Jordan B. King et al. JCHF 2016;4:

Slides:

Advertisements

Similar presentations

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Advertisements

Eric J Robinson, M.D. Cardiologist April 25, 2015

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Date of download: 6/25/2016 From: Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

CLINICAL DILEMMAS IN HEART FAILURE:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Noriko Kikuchi et al. JACEP 2016;2:

Takekuni Hayashi et al. JACEP 2016;2:27-35

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

Carolyn Y. Ho et al. JCHF 2015;3:

Belinda Gray et al. JCHF 2013;1:

Simon W. Rabkin et al. JACEP 2017;j.jacep

Wesley T. O’Neal et al. JACEP 2016;2:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Wayne L. Miller et al. JCHF 2013;1:

John A. Bittl et al. JACC 2016;68:

Jonathan M. Behar et al. JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

Prabhat Kumar et al. JACEP 2016;j.jacep

Ivan C. Gerling et al. JCHF 2013;1:

Connie W. Tsao et al. JCHF 2016;4:

Rami Doukky et al. JCHF 2016;4:24-35

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Neal A. Chatterjee et al. JCHF 2014;2:

P. Michael Grossman et al. JCIN 2009;2:

Gordon R. Reeves et al. JCHF 2017;j.jchf

William T. Abraham et al. JCHF 2015;3:

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Jerry D. Estep et al. JCHF 2013;1:

Simon W. Rabkin et al. JACEP 2017;3:

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Emilce Trucco et al. JACEP 2018;j.jacep

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Rami Doukky et al. JCHF 2016;4:24-35

Maneesh Sud et al. JCHF 2017;5:

John Rickard et al. JCHF 2013;1:

Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf

Leo F. Buckley et al. JCHF 2016;4:1-8

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Svend A. Mortensen et al. JCHF 2014;2:

Natasha A. Loghmanpour et al. JCHF 2016;4:

Khadijah Breathett et al. JCHF 2017;5:

Connie W. Tsao et al. JCHF 2016;4:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Ryan R. Reeves et al. JCIN 2015;8:

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Christian Madelaire et al. JCHF 2018;6:

Satoru Kishi et al. JCHF 2014;2:

Khadijah Breathett et al. JCHF 2017;5:

Constantijn Franssen et al. JCHF 2016;4:

Dennis M. McNamara et al. JCHF 2014;2:

Pamela E. Scott et al. JACC 2018;71:

Jeffrey Senfield et al. JACEP 2017;3:

Jackson J. Liang et al. JCHF 2014;2:

Orly Vardeny et al. JCHF 2016;4:

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Constantijn Franssen et al. JCHF 2016;4:

Summary of incremental cost-effectiveness ratio (ICERs) of rtPA therapy from the literature. Summary of incremental cost-effectiveness ratio (ICERs) of.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Presentation transcript:

Jordan B. King et al. JCHF 2016;4:392-402 ICER (Cost per QALY Gained) by Duration of Time in Model Changes in the incremental cost-effectiveness ratio (ICER) over the first 20 years after initiation of either sacubitril-valsartan or enalapril. The earliest measured ICER is at 3 years, which is the duration of follow-up observed in PARADIGM-HF. ICER = incremental cost-effectiveness ratio; PARADIGM-HF = Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; QALY = quality-adjusted life-year. Jordan B. King et al. JCHF 2016;4:392-402 American College of Cardiology Foundation